Drug treatment of malignant gliomas is limited by the intrinsic resistance of glioma stem cells (GSCs) to chemotherapy. GSCs isolated from human glioblastoma multiforme (GBM) expressed metabotropic glutamate receptors (mGlu3 receptors). The DNAalkylating agent, temozolomide, killed GSCs only if mGlu3 receptors were knocked down or pharmacologically inhibited. In contrast, mGlu3 receptor blockade did not affect the action of paclitaxel, etoposide, cis-platinum, and irinotecan. mGlu3 receptor blockade enabled temozolomide toxicity by inhibiting a phosphatidylinositol-3-kinase/nuclear factor-jB pathway that supports the expression of O 6 -methylguanine-DNA methyltransferase (MGMT), an enzyme that confers resistance against DNAalkylating agents. In mice implanted with GSCs into the brain, temozolomide combined with mGlu3 receptor blockade substantially reduced tumor growth. Finally, 87 patients with GBM undergoing surgery followed by adjuvant chemotherapy with temozolomide survived for longer time if tumor cells expressed low levels of mGlu3 receptors. In addition, the methylation state of the MGMT gene promoter in tumor extracts influenced survival only in those patients with low expression of mGlu3 receptors in the tumor. These data encourage the use of mGlu3 receptor antagonists as add-on drugs in the treatment of GBM, and suggest that the transcript of mGlu3 receptors should be measured in tumor specimens for a correct prediction of patients' survival in response to temozolomide treatment.
Malignant gliomas are highly infiltrating brain tumors that represent the third cause of cancer-related deaths among middle-aged men and the fourth cause of death among women between 15 and 34 years of age. The life expectancy of patients with grade IV astrocytoma (glioblastoma multiforme (GBM)) is 12 to 15 months, despite aggressive surgery, radiation, and chemotherapy. 1, 2 According to the cancer stem cell hypothesis, malignant gliomas arise from mutated, developmentally arrested multipotent progenitor cells ('glioma stem cells' or GSCs), which undergo self-renewal for an unlimited period of time and sustain tumor growth. [3] [4] [5] [6] GSCs are found in low percentage within the tumor mass, 7 but are intrinsically resistant to radiotherapy and chemotherapy because they cycle slowly and express high levels of proteins mediating mechanisms of drug resistance. 6, 8 This highlights the importance of designing new classes of agents that specifically target GSCs. Multiple intracellular signaling pathways regulate proliferation, differentiation, survival, and chemoresistance of GSCs, 9 which limits the value of smallmolecule inhibitors of individual pathways in the treatment of malignant gliomas. 10, 11 This encourages the search for novel therapeutic targets that lie upstream of signal propagation and have a strong impact on the fate of GSCs. We found that type-3 metabotropic glutamate receptors (mGlu3 receptors), which are coupled to G i /G o proteins, regulate GSCs and activate multiple signal-transduction pathways in GSCs and other cell types. 12, 13 Pharmacological blockade of mGlu3 receptors promotes astroglial differentiation of GSCs by facilitating the activity of bone morphogenetic proteins. 12 In mice implanted with GSCs into the brain, a 3-month systemic treatment with a potent mGlu3 receptor antagonist started at the time of cell implantation substantially reduced tumor growth. 12 These data are interesting, but they have limited value in translational medicine because the treatment of malignant gliomas in humans usually starts when the tumor is already fully developed. In pilot studies, we could not see any significant effect of the mGlu3 receptor antagonist when treatment started weeks after GSC implantation. We decided to examine whether mGlu3 receptor blockade could facilitate the cytotoxic action of conventional chemotherapeutic agents becoming effective as add-on drugs in the treatment of malignant gliomas. We report here that mGlu3 receptor blockade enables the cytotoxic action of the DNA-alkylating agent, temozolomide, on GSCs, and the combination of the two drugs is effective in reducing tumor growth in mice implanted with GCSs. In addition, we show that the expression level of mGlu3 receptors in tumor samples is inversely related to overall survival (OS) in patients with GBM undergoing surgery followed by radiotherapy and temozolomide treatment.
Results mGlu3 receptors restrain temozolomide toxicity in cultured human GCSs. We used five clones of GSCs (named A-E) isolated from surgical specimens of human GBM. Cultured GCSs grown under proliferating conditions formed floating 'tumor spheres', in which 475-80% of cells expressed the stem cell markers, nestin, Musashi homolog 1 (Musashi1), and sex-determining Y-box 2 (Sox-2) (immunostaining of cells from clone 'E' are shown in Figure 1a ; see also Hadjipanayis and Van Mier 9 ). A smaller percentage of cells (22-29% of cells from clones B to E, and 40% of cells from clone A) were labeled by the AC133 antibody recognizing a glycosylated epitope of CD133. 4 Tumorigenicity of cells of clone E was confirmed by an in vivo dilution assay (Figure 1b) .
Undifferentiated GSCs from all five clones expressed mGlu3, but not mGlu2, receptors (Figures 2a and b) . mGlu3 receptors are coupled to G i proteins, and their activation inhibits adenylyl cyclase activity, and stimulates the mitogenactivated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PtdIns-3-K) pathways. 13 GCSs dissociated from the tumor spheres were starved from mitogens, and then challenged with the selective mGlu2/3 receptor agonist, (-)-2-oxa-4-aminobicyclo[3.1.0]exhane-4,6-dicarboxylic acid (LY379268). This treatment inhibited forskolin-stimulated cyclic adenosine monophosphate (cAMP) formation and increased levels of phosphorylated extracellular signalregulated kinase (ERK)1/2 and phosphorylated Akt. All these effects were reversed by the mGlu2/3 receptor antagonist, (2S 
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Phase Contrast Left striatum 0.01x10 6 GSCs 0.05x10 6 GSCs 0.1x10 6 GSCs 0.5x10 6 GSCs Figure 1 Expression of stem cell markers and tumorigenicity of GSCs isolated from clone E. Immunocytochemical analysis of Musashi1 and Sox-2 is shown in (a). Fluorescence staining is in green; DAPI, used as a counterstaining, is blue; phase-contrast microscopy is also shown. In vivo limiting dilution assay of GSCs implanted in the striatum of mice killed 3 months later is shown in (b). Representative images show the presence of 0.01, 0.05, 0.1, and 0.5 Â 10 6 GFP þ GSCs in the striatum of implanted mice mGlu3 receptors and malignant gliomas C Ciceroni et al clones). At least in clone E, treatment with LY341495 also reversed the increase in phospho-ERK1/2 and phospho-Akt levels induced by epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) (Figures 2d and e) . LY341495 did not affect EGF receptor (EGFR) autophosphorylation in response to EGF (Figure 2f ), suggesting that the drug had no direct off-target effects on EGFRs. Thus, these data suggest that endogenous activation of mGlu3 receptors has a permissive role on the stimulation of the MAPK and PtdIns-3-K pathways by mitogens. GSCs were treated with temozolomide, a DNA-alkylating agent, which is widely used in the adjuvant chemotherapy of malignant gliomas.
14 Temozolomide (2.5-250 mM) did not affect cell viability when applied alone, but became toxic when combined with LY341495 and (3S)-1-(5-bromopyrimidin-2-yl)-N-(2,4-dichlorobenzyl)pyrrolidin-3-amine methanesulfonate hydrate (LY2389575), two drugs that block mGlu3 receptors. The mGlu2/3 receptor agonist, LY379268, was inactive on its own, but reversed the permissive action of LY341495 on temozolomide toxicity (Figures 2g-j and Supplementary Figure 2) . siRNA-induced knockdown of mGlu3 receptors also enabled temozolomide toxicity, and the antagonist LY341495 did not further amplify toxicity in cells deprived of mGlu3 receptors (Figure 2k ). These data indicate that activation of mGlu3 receptors by endogenous glutamate (extracellular glutamate concentrations: 4-10 mM; n ¼ 6) restrains the toxic action of temozolomide, and that GSCs become sensitive to temozolomide only if mGlu3 receptors are blocked or deleted.
Searching for the underlying mechanism(s), we treated GSCs with molecules that interfere with the three major signaling pathways activated by mGlu3 receptors, that is, inhibition of adenylyl cyclase activity, activation of the MAPK pathway, and activation of the PtdIns-3-K pathway. The cellpermeable cAMP analog, 8-Br-cAMP (1 mM), did not affect the synergism between mGlu3 receptor blockade and temozolomide, and the MAPK kinase inhibitor, UO126 (30 mM), had little, if any, effect on temozolomide toxicity (Figure 3a) . In contrast, the PtdIns-3-K inhibitor, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one hydrochloride (LY294002), had a permissive action on temozolomide toxicity, thus mimicking the effect of mGlu3 receptor blockade. The actions of LY294002 and LY341495 were less than additive (Figure 3a) , suggesting that mGlu3 receptor blockade facilitates cytotoxicity by limiting the activation of the PtdIns-3-K pathway. This hypothesis was supported by the use of GSCs expressing a constitutively active form of the PtdIns-3-K substrate, Akt 15 (see Supplementary Figure 3 ). In these cells, in which the PtdIns-3-K pathway was active in spite of mGlu3 receptor blockade, the synergism between LY341495 and temozolomide was largely attenuated (Figure 3b) . We extended the study to signaling pathways that lie downstream of Akt and are known to regulate viability and chemosensitivity of GSCs and glioma cells. Akt is known to activate nuclear factor-kB (NF-kB) by phosphorylating the IkB kinase, 16 and NFkB activation limits the proapoptotic activity of DNAalkylating agents in glioma cells. 17 Here, treatment with temozolomide activated NF-kB, as shown by increased levels of IkB phosphorylation. This effect was reversed by LY341495 or by the PtdIns-3-K inhibitor, LY294002 (Figures 3c and d) . The specific NF-kB inhibitor, 4-methyl-N1-(3-phenyl-propyl)-benzene-1,2-diamine (JSH-23), 18 enabled temozolomide toxicity and occluded the permissive action of LY341495 in GSCs (Figure 3e ). Similar effects were obtained with salicylic acid (Supplementary Figure 4) , which also inhibits NF-kB. 19 As opposed to LY341495, JSH-23 could still enhance temozolomide toxicity in GSCs expressing the constitutively active form of Akt (Figure 3f ), indicating that NF-kB lies downstream of Akt in the pathway that restrains temozolomide toxicity. Akt also regulates the mammalian target of rapamycin (mTOR), which promotes mRNA translation and protein synthesis by phosphorylating p70 S6 kinase and 4E-BP1. 20 mTOR supports the survival of glioblastoma cells, 20 and inhibitors of the Akt/mTOR pathway are under development for the treatment of malignant gliomas. 21 Here, however, the selective mTOR inhibitor, rapamycin, did not mimic, but rather abolished the permissive action of mGlu3 receptor blockade on temozolomide toxicity (Supplementary Figure 5) . mGlu3 receptors support MGMT expression in cultured human GCSs challenged with temozolomide. We examined whether the permissive effect of mGlu3 receptor blockade was specific for temozolomide or could be extended to other chemotherapeutic agents. GSCs grown under proliferating conditions were treated with etoposide, irinotecan, the irinotecan metabolite, 7-ethyl-10-hydroxycamptothecin (SN38), cisplatin, or paclitaxel alone or combined with LY341495. These treatments had no -methylguanine-DNA methyltransferase (MGMT), which removes DNA adducts generated by alkylating agents. 22 Our GSC clones expressed MGMT. Treatment of GSCs with temozolomide alone increased MGMT mRNA levels at 3 h and slightly reduced MGMT protein levels at 24 and 48 h as a result of the loss of protein associated with DNA repair. 22 The transcript of MGMT failed to increase, and MGMT protein levels were markedly reduced when temozolomide was combined with the mGlu3 receptor antagonist, LY341495 (Figures 5a and b and Supplementary Figure 7) . Again, the action of LY341495 was mimicked by an siRNA-induced knockdown of mGlu3 receptors (Figure 5c Pharmacological blockade of mGlu3 receptors reduces tumor growth in mice infused with GCSs. To strengthen the biological significance of our findings, we performed in vivo studies on mice implanted with human GSCs in the brain parenchyma. Cells engineered to express the green fluorescent protein (GFP) were implanted into the left caudate nucleus of nude mice (5 Â 10 5 cells/5 ml/5 min). We carried out two sets of experiments, each with four groups of 10 mice. All mice were subcutaneously implanted with osmotic minipumps releasing LY341495 (3 mg/kg per day for 28 days) or saline. At the same time, mice received three injections of temozolomide (70 mg/kg, intraperitoneally) or vehicle every other day during the first week following minipump implantation. In one experiment, mice received drug treatments 15 days after GSC implantation and were killed 30 days later (i.e. 45 days after cell implantation) (Figure 7a ). Alternatively, mice were treated with drugs 45 days after GSC implantation and killed 30 days later (i.e. 75 days after cell implantation) (Figure 7b ). Control mice, that is, mice implanted with a minipump releasing saline and receiving vehicle intraperitoneally, showed the presence of GFP þ cells bearing the typical morphology of glioma cells, as assessed by hematoxylineosin staining. In mice killed 45 days after cell implantation, tumor cells were confined to the medial portion of the caudate nucleus close to the wall of the lateral ventricle (Figure 7a , a1, and a2). In mice killed at 75 days, tumor cells formed an infiltrating mass in the ipsilateral caudate nucleus and, in most of the animals, they spread to the ipsilateral septum and to the ipsi-and contralateral portion of the corpus callosum (Figure 7b and b1-3 ). Using this treatment paradigm, we did not see any significant effect of LY341495 per se on tumor growth. Treatment with temozolomide alone was also ineffective. In contrast, a combined treatment with temozolomide and LY341495 significantly reduced tumor growth (Figures 7a2 and b3 and Supplementary Figure 8) , in good agreement with in vitro data.
Low levels of mGlu3 receptor mRNA in tumor specimens are predictive of long survival in patients with GBM receiving adjuvant temozolomide. We searched for an association between expression of mGlu3 receptors in tumor samples and survival of patients with GBM undergoing surgery followed by radiotherapy and adjuvant temozolomide. The transcript of mGlu3 receptors was measured by quantitative PCR in selected regions of the tumor in a cohort of 87 patients (Supplementary Table 1 ). 'Normal' mGlu3 receptor mRNA levels were defined as those measured in autoptic brain samples with no histological abnormalities (n ¼ 20). Levels of mGlu3 receptor mRNA below the normal range were detected in 42 GBMs (48.3%), whereas in 45 cases (51.7%) mRNA levels either fell within the normal range (n ¼ 14) or were higher than normal (n ¼ 31) (Figure 8a ). The Kaplan-Meier analysis of OS on mGlu3 receptor mRNA expression predicted a prolonged OS (Po0.0001; HR: 3.129; 95% CI: 1.808-5.414) in the group of patients with mGlu3 receptor mRNA expression below the normal range (Figure 8b ). Interestingly, all five patients who survived longer than 36 months harbored tumors with mGlu3 receptor mRNA below the normal range. On multivariate analysis, Karnofsky performance score, Ki-67, and mGlu3 receptor mRNA emerged as independent predictors for OS (P ¼ 0.000671, 0.000504, and 0.001374, respectively) (Supplementary Table 2 ). We also stratified patients for mGlu3 receptor expression and the methylation state of MGMT promoter. The group with low mGlu3 receptor mRNA levels and methylated MGMT promoter showed a significantly higher OS as compared with the group with low mGlu3 receptor mRNA and unmethylated MGMT promoter (P ¼ 0.0020). Patients with high/'normal' mGlu3 receptor mRNA and methylated MGMT promoter showed a low OS, regardless of the methylation state of MGMT promoter (Figure 8c ).
Discussion
The glutamate released from glioma cells appears to play a central role in the malignant phenotype of gliomas by causing excitotoxic neurodegeneration and epileptic seizures via the activation of neuronal glutamate receptors, [25] [26] [27] and by regulating glioma cell proliferation and perivascular glioma invasion via the autocrine/paracrine activation of AMPA (2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid) receptors. [28] [29] [30] Our data disclose a new function of glutamate in regulating the biology of GSCs. The amount of glutamate released from GSCs in culture (extracellular concentrations ¼ 4-10 mM) was sufficient to activate mGlu3 receptors, which were expressed and functional in all our GSC clones (EC 50 values for glutamate at mGlu3 receptors are reported in Schoepp et al.
31.
). All our GSC clones were highly resistant to the cytotoxic activity of temozolomide unless the mGlu3 receptor was blocked. Inhibition of PtdIns-3-K and its effector pathways could also facilitate temozolomide toxicity, as expected. 32 What is novel here is that PtdIns-3-K was tightly regulated by mGlu3 receptors, and that receptor blockade was sufficient to suppress temozolomide-induced MGMT expression and to enable temozolomide toxicity. This suggests that, at least under our conditions, other endogenously active receptors coupled to PtdIns-3-K could not rescue temozolomide-induced MGMT expression when mGlu3 receptors were blocked. NF-kB, which is activated by the PtdIns-3-K/Akt pathway, 15 is one of the strongest inducers of MGMT expression. In recombinant cells, NF-kB/p65 homodimers enhance MGMT expression sevenfold more than AP1/ c-jun, and, remarkably, induction of MGMT by NF-kB is unaffected by the methylation state of the MGMT gene promoter. 33 We have shown that mGlu3 receptor blockade substantially reduced NF-kB binding to the MGMT gene promoter in GCSs treated with temozolomide, raising the interesting possibility that activation of mGlu3 receptors may support MGMT expression even if the MGMT promoter is hypermethylated. Two sets of data are consistent with this hypothesis: (i) treatment with LY341495 inhibited temozolomide-induced MGMT expression and enabled temozolomide toxicity also in GSCs of clone 'A', which derived from a tumor in which the MGMT gene promoter was methylated; and (ii) the survival of temozolomide-treated patients with high levels of mGlu3 receptor mRNA in the tumor was totally unaffected by the methylation state of the MGMT promoter (see Figure 8c ). Our data also suggest that hypermethylation of the MGMT promoter is a positive predictor of survival only in patients with low mGlu3 receptor expression in tumor specimens. The dependency of MGMT on the expression levels of mGlu3 receptors might help to explain the controversial data on the correlation between MGMT promoter methylation and patients' survival. [34] [35] [36] [37] [38] [39] [40] Our data may pave the way to a new strategy in the pharmacological treatment of malignant gliomas because mGlu3 receptor antagonists could be added to temozolomide or other DNA-alkylating agents for the optimization of adjuvant chemotherapy. The evidence that a combined treatment with temozolomide and LY341495 was still efficacious in restraining tumor growth when initiated 45 days after cell implantation in mice is particularly promising for translation into medical practice because of the long interval between onset and treatment of malignant gliomas.
As opposed to small-molecule inhibitors of intracellular enzymes or transcription factors that regulate chemoresistance, such as PtdIns-3-K or NF-kB, mGlu3 receptor antagonists are expected to be safe and well tolerated, as shown by all clinical trials with mGlu receptor ligands in neurological and psychiatric disorders. 13 Accordingly, we did not see signs of systemic toxicity or motor impairment in mice treated with 3 mg/kg per day of LY341495, and, in acute experiments, naive mice survived to doses of LY341495 as high as 300 mg/kg, intraperitoneally (not shown).
In conclusion, we have demonstrated that the mGlu3 receptor, a particular type of G-protein-coupled receptor activated by glutamate, restrains temozolomide toxicity by exerting a permissive role on temozolomide-induced MGMT expression in GSCs. We propose a hypothetical model in which the convergence of at least two intracellular pathways is required for NF-kB activation and MGMT induction in response to temozolomide. One of this pathway might be directly linked to DNA damage caused by temozolomide via the activation of the ataxia-telangiectasia-mutated protein complex or other mechanisms. [41] [42] [43] [44] The other pathway is activated by the endogenous glutamate acting at mGlu3 receptors and is mediated by PtdIns-3-K (see Figure 6e) . Thus, glutamate, the major excitatory neurotransmitter in the CNS, is not only involved in the regulation of tumor invasion and cell proliferation but also acts as a critical regulator of the intracellular signaling pathways that mediate chemoresistance, thereby limiting the clinical efficacy of standard chemotherapy with DNA-alkylating agents.
Materials and Methods
Temozolomide, cisplatinum, irinotecan, etoposide, paclitaxel, 8Br-cAMP, and O 6 -benzylguanine were purchased from Sigma-Aldrich (St. Louis, MO, USA). UO-126 was purchased from Promega (Milano, Italy). LY341495, LY379268, LY294002, and SN38 were purchased from Tocris Cookson Ltd (Bristol, UK). LY2389575 was kindly provided by Eli Lilly and Company (Indianapolis, IN, USA) to FN. JSH-23 and sodium salicylate were purchased from Santa Cruz Technology (Santa Cruz, CA, USA).
Cultures of human GSCs. Human GSCs were derived from five adult human glioblastoma bioptic samples (after obtaining informed consent) classified according to the guidelines of the World Health Organization. In three of these samples, giving raise to GSC clones 'B', 'D', and 'E', the MGMT gene promoter was unmethylated. In the glioblastoma sample giving raise to GSC clone 'A', the MGMT gene promoter was methylated. We have no information on the methylation state of the MGMT gene promoter in the remaining glioblastoma sample giving raise to clone 'C'. Undifferentiated GBM stem cells were obtained through mechanical dissociation of the tumor tissue and cultured in a serum-free medium. Briefly, tissue chunks were collected in Dulbecco's modified Eagle medium (DMEM)/F12, homogenized through vertical blade cuts, and then centrifuged for 3 min at 1000 r.p.m.; the pellet was mechanically dissociated to a single-cell suspension. Cells were re-suspended in serum-free enriched DMEM/ F12 medium in the presence of 10 ng/ml of human recombinant EGF and 20 ng/ml of human recombinant bFGF, and plated in 75 cm 2 culture flask (Falcon BD, Franklin Lakes, NJ, USA). Under these culture conditions, cells proliferated and aggregated into tumor spheres, and maintained an undifferentiated state, as indicated by morphology and expression of the stem cell markers. At 1 week after plating, primary tumor spheres were collected, mechanically dissociated, and replated under the same culture conditions to eliminate short-term dividing precursors.
Immunocytochemical analysis of Musashi1 and Sox-2. Cells were fixed with 4% paraformaldehyde and stained with antibodies directed against Sox-2 (R&D Systems, Minneapolis, MN, USA; 1 : 200) or MMusashi1 (R&D Systems; 1 : 200). As secondary antibodies, goat anti-rabbit fluorescein isothiocyanateconjugated IgG (Chemicon, Temecula, CA, USA; 1 : 100) were used. Nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI) (Vectashield mounting medium with DAPI; Vector Laboratories, Burlingame, CA, USA).
RT-PCR analysis of mGlu2 and mGlu3 receptor mRNA. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis was performed using the following primers: mGlu2 -forward, 5
0 . All transcripts obtained spanned around 100 bp.
Western blot analysis. Cells were lysed using a Triton X-100 lysis buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 1 mM sodium orthovanadate, 50 mM sodium fluoride, and 10 mM b-glycerophosphate) for 15 min, and cell lysates were clarified by centrifugation (12 000 r.p.m. for 10 min). Proteins (40 mg) were separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis, blotted onto nitrocellulose membranes, and probed with the following primary antibodies: rabbit polyclonal anti-mGlu2/3 receptor (Upstate Biotechnology, Lake Placid, NY, USA; 1 : 750); mouse monoclonal antiphospho-ERK1/2 (Cell Signaling Technology, Danvers, MA, USA; 1 : 500), rabbit polyclonal anti-ERK1/2 (Santa Cruz Biotechnology, Tebu, France; 1 : 2000); rabbit polyclonal anti-phospho-Akt (Cell Signaling; 1 : 500); rabbit polyclonal anti-Akt (Cell Signaling; 1 : 1000); rabbit polyclonal anti-MGMT (Cell Signaling; 1 : 500); mouse monoclonal anti-b-actin (Sigma-Aldrich, St. Louis, MO, USA; 1 : 2500); rabbit polyclonal anti-phospho-Tyr1068-EGF receptor (EGFR) (Cell Signaling; 1 : 500); rabbit polyclonal anti-EGFR (Cell Signaling; 1 : 1000); mouse monoclonal antiphospho-Ser32/Ser36-IkBa (Cell Signaling; 1 : 1000); rabbit polyclonal antiphospho-Ser9-glycogen synthase kinase-3b (GSK3b) (Cell Signaling; 1 : 500); and rabbit polyclonal anti-GSK3b (Cell Signaling; 1 : 1000).
Measurement of extracellular glutamate levels. Analysis of glutamate in the medium of GSCs was performed by precolumn derivatization with o-phthalaldehyde and mercaptoethanol, followed by high-performance liquid chromatography with fluorescence detection. A measure of 10 ml sample aliquots were diluted with 0.1 M HCl and mixed with equal volumes of fluorescent reagent. The mixture was kept at room temperature for 1 min to derivatize the sample before being injected into the column by a 20 ml loop. The system utilized an autosampler 507 (Beckman Instruments Inc., Fullerton, CA, USA), a programmable solvent module 126 (Beckman Instruments Inc.), an analytical reverse phase C-18 column at 30 1C (Ultrasphere ODS 3 mm Spherical, 80 Å pore, 2 mm Â 150 mm; Beckman Instruments Inc.), an RF-551 spectrofluorimetric detector (Shimadzu, Japan), and a computer running a Gold Nouveau software (Beckman Instruments Inc.). The excitation and emission wavelengths were set at 360 and 450 nm, respectively. The mobile phase consisted of: (A) 50 mM sodium phosphate, pH 7.2, containing 10% methanol and (B) 50 mM sodium phosphate, pH 7.2, containing 70% methanol, at a flow rate of 0.3 ml/min. Gradient elution consisted of 98% A and 2% B initially for 10 min, was then increased to 98% B over 1 min, maintained for 1 min to elute other substances, and then returned to the initial conditions before running the next sample. From peak areas, culture medium concentrations of glutamate were calculated by the use of external standards.
Measurement of intracellular cyclic AMP levels. Cells were incubated in Krebs-Henseleit buffer containing 0.5 mM isobutylmethylxantine for 15 min at 37 1C under constant oxygenation. After the addition of forskolin and/or mGlu receptor ligands, the incubation was continued for 20 min. The reaction was stopped by the addition of an equal volume of ice-cold 0.8 N HClO 4 . Samples were sonicated and centrifuged at low speed. After the addition of K 2 CO 3 , samples were centrifuged and supernatants used for assessment of cAMP by radioimmunoassay (GE Healthcare, Milano, Italy).
Assessment of cell viability
MTT assay : Cell viability was assessed by using the Cell Titer 96 NonRadioactive Cell Proliferation Assay (Promega) according to the manufacturer's protocol. The assay is based on the reduction of 3-(4,5-dimethylthioazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) to a colored formazan product, which is measured by spectrophotometry at a wavelength of 570 nm. Cells were plated in 96-well plates and treated as indicated. At the end of the treatments, cells were incubated at 37 1C in a 5% CO 2 incubator. Metabolically active cells were detected by adding 15 ml of dye solution to each well. After 1 h of incubation, 100 ml of solubilizing stop solution was added to the wells and the plates were read on a Multilabel Counter (Victor2; Perkin-Elmer, Waltham, MA, USA). Cytofluorimetric analysis of aneuploid DNA : FACS analysis of DNA ploidy was carried out using a Coulter Elite flow cytometer after staining with propidium iodide (50 mg/ml) and treatment for 1 h with RNAse (100 mg/ml). LDH release : Extracellular lactate dehydrogenase (LDH) activity was measured using a commercial kit (Roche Diagnostics SpA, Milano, Italy).
Assessment of NF-jB binding to responsive sequences in the MGMT promoter. Analysis of interaction between NF-kB and its two binding sites on the MGMT gene promoter was assessed by chromatin immunoprecipitation (ChIP). Crosslink between proteins and DNA was obtained with 1% formaldehyde, and ChIP was performed by a commercial kit (EpiTect ChIP OneDay Kit; SA Biosciences, Frederick, MD, USA) and a ChIP-grade NF-kB antibody (Cell Signaling Technology, Danvers, MA, USA; 1 : 500). For real-time PCR analysis of immunoprecipitated chromatin, we used two pairs of specific primers for the NF-kB binding sites on the MGMT gene promoter (GPH1001966( þ )09A and GPH1001966( þ )10A; SA Biosciences). Data, obtained with the DDCt method for quantifying chromatin enrichment and normalized for input chromatin and background levels, were expressed as fold enrichment, and compared by measuring fold change in site occupancy between controls and treatments.
Silencing of mGlu3 receptors. mGlu3 receptor gene was silenced in human GBM stem cells by using a commercial kit supplied by Qiagen (Life Sciences, Milan, Italy). The following siRNAs were used: siRNA '1' (Hs_GRM3_1) -sense, 5 0 -GGUCCUUGUUGUAACUAAUTT-3 0 ; antisense, 5 0 -AUUAGUUACAA CAAGGACCTA-3 0 ; siRNA '2' (Hs_GRM3_4) -sense, 5 0 -GCGCCAAACUCAGU GAUAATT-3 0 ; antisense, 5 0 -UUAAUCACUGAGUUUGGCGCTG-3 0 . Cells were seeded at a density of 5 Â 10 5 in 100 ml of culture medium in 96-well plates and incubated at 37 1C. After 24 h, a mix containing 150 ng of siRNA and 1 ml HiPerFect Transfection Reagent (Qiagen) was then added to the culture medium (final concentration 5 nM per well). Transfected and control cells were treated with temozolomide (250 mM) alone or in combination with LY341495 (100 nM). Cell viability was measured 24 and 48 h afterwards by MTT analysis.
Transient transfections. Transient transfections with the MGMT plasmid construct or the constitutively active Akt plasmid constructs were performed by the LipofectAMINE method (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. GSCs were seeded at a density of 7.5 Â 10 3 in 96-well plates and incubated, 1 day after plating, in Optimem with 0.5 ml of LipofectAMINE (Life Technologies Europe, Monza, Italy) reagent and 0.2 mg of plasmid construct for 4 h per well.
Evaluation of tumor growth in nude mice implanted with GFP þ GBM stem cells into the brain. Experiments were performed in accordance with the Guidelines for Animal Care and Use of the National Institutes of Health. Male CD1 nude mice (Charles River, Calco, Italy; 20-22 g, body weight), and were kept under controlled conditions (temperature ¼ 22 1C; humidity ¼ 40%) on a 12-h light/dark cycle with food and water ad libitum. GSCs were engineered to express the GFP as described previously. 45 GFP þ GSCs were stereotaxically implanted into the left caudate nucleus using the following coordinates: 0.6 mm anterior to bregma; 1.7 mm lateral to the midline; and 3.5 mm ventral from the surface of skull according to the atlas of Franklin and Paxinos, under ketamine (100 mg/kg, intraperitoneally)/xylazine (10 mg/kg, intraperitoneally) anesthesia. For limiting dilution assay, GCSs (0.01, 0.05, 0.1, or 0.5 Â 10 6 cells/ 5 ml) were implanted at an infusion rate of 1 ml/min. The needle was left 5 min in place after cell infusion before being withdrawn. Animals were killed 3 months after GSC implantation. In another set of experiments, GCSs (0.5 Â 10 6 cells/5 ml) were implanted at an infusion rate of 1 ml/min. The needle was left 5 min in place after cell infusion before being withdrawn. At 15 or 45 days after cell implantation, mice were implanted with osmotic minipumps (Alzet, releasing 250 nl/h per 28 days), filled with saline or LY341495 (3 mg/kg per day), and were treated with three injections of saline or temozolomide (70 mg/kg, intraperitoneally, every other day). Mice were killed 1 month later. Histological analysis was performed by hematoxylin/eosin staining. The growth of GSCs was assessed by fluorescence microscopy of GFP þ GSCs according to the following score: 0, no GFP þ GSCs; 1, presence of GFP þ GSCs in the injection site; 2, presence of GFP þ GSCs in the medial portion of the caudate nucleus close to the wall of the lateral ventricle; 3, presence of GFP þ GSCs in about 50% of the left caudate nucleus; 4, presence of GFP þ GSCs in the whole caudate nucleus and infiltrating the ipsilateral septum; 5, presence of GFP þ GSCs in the whole caudate nucleus infiltrating the ipsilateral septum and corpus callosum; 6, presence of GFP þ GSCs in the whole caudate nucleus infiltrating the ipsilateral septum and corpus callosum and a partial infiltration of the contralateral corpus callosum; and 7, presence of GFP þ GSCs in the whole caudate nucleus infiltrating the ipsilateral septum and corpus callosum and a complete infiltration of the contralateral corpus callosum.
Patient population. We enrolled 87 adult patients who underwent craniotomy for resection of histologically confirmed GBM (World Health Organization grade IV) in the supratentorial compartment, and who had been treated postoperatively with adjuvant radiotherapy and temozolomide at Università Cattolica del Sacro Cuore (Rome, Italy). All patients provided written informed consent according to the Declaration of Helsinki (BMJ 1991; 302: 1194) and to the research proposals approved by the Ethical Committee of the Università Cattolica del Sacro Cuore (Rome, Italy). Patients with secondary GBM were not included. Patients were 30 to 80 years old at the time of primary surgery (median age: 58 years); 57 were men and 30 women. All patients received radiotherapy to limited fields (2 Gy per fraction, once a day, 5 days a week, 60 Gy total dose) and adjuvant temozolomide after surgery. 7 To minimize contamination by normal cells, the tumor areas selected for DNA extraction contained at least 80% disease-specific cells. OS was calculated from the date of surgery to death or end of follow-up. Immunohistochemical patterns were established as reported previously. 45 The Ki-67 labeling index was defined as the percentage of positive nuclei of a total of 2000 tumor cells counted using an eyepiece grid. The positive nuclei were counted without prior knowledge of the patient prognosis-related information. The methylation state of the MGMT gene promoter was assessed as described previously. 46 RNA extraction and analysis of mGlu3 receptor expression in human brain tissue. After being deparaffinized, three 10-mm-thick slides were digested overnight at 55 1C in 200 ml of TENS buffer 1 Â (10 mM Tris, pH 7.4, 10 mM EDTA, 100 mM NaCl, 1% SDS) with 100 mg/ml proteinase K and RNA was then extracted by RNeasy mini kit (Qiagen), according to the manufacturer's protocol. We assessed the quantity and quality of the RNA spectrophotometrically (E260, E260/E280 ratio, spectrum 220-320 nm; Biochrom, Cambridge, UK) and by separation on an Agilent 2100 Bioanalyzer (Palo Alto, CA, USA). mGlu3 receptor mRNA levels were measured by using a One-Step qRT-PCR KAPA SYBR FAST kit (Kapa Biosystems, Boston, MA, USA) according to the manufacturer's protocol. The assay was performed on 67 GBMs and on 20 samples of human brain tissue showing no abnormalities at histology (normal control). Briefly, 100 ng of mRNA from each sample was reverse-transcribed and amplified in a 25 ml reaction volume with the following components: 12.5 ml of 2 Â KAPA Sybr FAST qPCR master mix, 0.5 ml of KAPA RT mix (50 Â ), 200 nM . b-Actin amplification was used as internal control. Specificity of products was assessed by direct sequencing, using the same primers used for PCR amplification. The average obtained for mGlu3 receptor was normalized to the average amount of b-actin for each sample to determine relative changes in mRNA expression (the ratio was calculated using the 2 -DCt method).
